Abstract
Aspirin and salicylate are transformed by stimulated human polymorphonuclear leucocytes (PMN), likely to be found at inflammatory sites, into both 2,3- and 2,5-dihydroxybenzoates (DHB). These DHB inhibit both the production of hydrogen peroxide by stimulated human PMN and prostaglandin (PG) E2 by activated rat macrophages. In contrast, DHB stimulated production of interleukin (IL)-1 and tumour necrosis factor (TNF) but inhibited IL-6 production by rat macrophages. These effects were probably a consequence of PGE2 inhibition. Gentisate (2,5-DHB) and homogentisate (a tyrosine metabolite) inhibited the lymphoproliferative action of IL-1. Some related phenols, e.g. 5-aminosalicylate, inhibited H2O2 production but had little effect on PGE2 production.
These findings suggest that the local synthesis of DHB may contribute to the overall anti-inflammatory activity of salicylate, which (unlike aspirin) has little direct effect on PG production.
Similar content being viewed by others
References
J. R. Vane,The mode of action of aspirin-like drugs. Agents and Actions8, 430–431 (1978).
B. M. Babior,The respiratory burst oxidase. Trends Biochem. Sci.12, 241–243 (1987).
T. R. Green and K. L. Pratt,A reassessment of the product specificity of the NADPH:O 2 oxidoreductase of human neutrophils. J. Biol. Chem.261, 6010–6015 (1987).
C. E. Cross,Oxygen radicals in human disease. Ann. Internatl. Med.107, 526–545 (1987).
E. Shacter, R. L. Lopez and S. Pati,Inhibition of the myeloperoxidase-H 2 O 2 −Cl − system of neutrophils by indomethacin and other non-steroidal antiinflammatory drugs. Biochem. Pharmacol.41, 975 984 (1991).
C. A. Dinarello,Interleukin-1 and its biologically related cytokines. Adv. Immunol.44, 153–205 (1989).
S. Akira, T. Hirano, T. Taga and T. Kishimoto,Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J.4, 2860–2867 (1990).
S. B. Mizel, J. M. Dayer, S. M. Karne and S. E. Mergenhagen,Stimulation of rheumatoid synovial cell collagensae and prostaglandin production by partially purified lymphocyte-activating factor (Interleukin-1). Proc. Natl. Acad. Sci. USA78, 2474–2477 (1981).
A. Ferrante, M. Nandoskar, A. Walz, D. H. B. Goh and I. C. Kowanko,Effects of tumour necrosis factor alpha and interleukin-1 alpha and beta on human neutrophil migration, respiratory burst and degranulation. Int. Archs. Allergy Appl. Immun.86, 82–91 (1988).
T. Y. Shen,Prostaglandin synthetase inhibitors I. InAntiinflammatory Drugs. (Eds. J. R. Vane and S. H. Ferrera) pp. 306–407, Springer, Berlin (1979).
P. F. A. Wright and B. G. Priestly,An HPLC-ECD assay of hydroxylated salicylate for the detection of hydroxyl radicals. Clin. Exp. Pharm. Physiol. (Suppl.)10, (1987).
A. L. Sagone, R. M. Husney, M. S. O'Dorosio and E. M. Metz,Mechanisms for the oxidation of reduced glutathione by stimulated granulocytes. Blood63, 96–104 (1984).
N. P. Hurst, J. K. French, A. Bell, G. Nuki, M. L. O'Donnell, W. H. Betts and L. G. Cleland,Differential effects of mepacrine, chloroquine and hydroxychloroquine on superoxide anion generation, phospholipid methylation and arachidonic acid release by human blood monocytes. Biochem. Pharmacol.35, 3083–3089 (1986).
D. R. Haynes, I. R. Garrett and B. Vernon-Roberts,Effect of gold salt treatment on receptor binding activity of monocytes and macrophages isolated from rats with adjuvant arthritis. Rheumatol. Int.8, 159–164 (1988).
D. R. Haynes, 1. R. Garrett, M. W. Whitehouse and B. Vernon-Roberts,Do gold drugs inhibit interleukin-1? Evidence from an in vitro lymphocyte activating factor assay. J. Rheumatol.15, 775–778 (1988).
S. Nakai, K. Mizuno, M. Kaneta and Y. Hirai,A simple, sensitive bioassay for the detection of interleukin-1 using human melanoma A375 cell line. Biochem. Biophys. Res. Comm.154, 1189–1196 (1988).
N. Matthews and M. L. Neale, Cytotoxicity assays for tumour necrosis factor and lymphotoxin. InLymphokines and Interferons, a Practical Approach (Eds. M. J. Clements, A. G. Morris and A. J. H. Ghearing) pp. 221–225, IRL Press, Oxford 1987.
P. M. Bartold and D. R. Haynes,Interleukin-6 production by human gingival, fibroblast. J. Peridont. Res.26, 339–345 (1991).
R. W. Kelly, S. Deam, M. J. Cameron and R. F. Seamark,Measurement by radioimmunoassay of prostaglandins as their methyl oximes. Prostaglandins Leukotr. Med.24, 1–14 (1978).
D. A. Bass, J. W. Parce, L. R. Dechatelet, P. Szejda, M. C. Seeds and M. Thomas,Flow cytometric studies of oxidative product formation by neutrophils: A graded response to membrane stimulation. J. Immunol.126, 1910–1917 (1983).
G. W. Snedecor and W. G. Cochran, Statistical Methods, 8th Edition pp. 84–86, Iowa State University Press, Ames, Iowa 1989.
P. M. Brooks, W. F. Keen and W. W. Buchanan,Salicylates. InThe Clinical Pharmacology of Anti-Inflammatory Agents, pp. 46–58. Taylor and Francis, London. 1986.
L. G. Cleland, M. W. Whitehouse and W. H. Betts,Gentisate, a salicylate metabolite with antioxidant properties. Drugs Exp. Clin. Res.XI, 273–280 (1985).
M. Grootveld and B. Halliwell,Aromatic hydroxylation as a measure of hydroxyl radical formation in vivo. Biochem. J.237, 499–504 (1986).
E. M. Kapp and A. F. Coburn,Urinary metabolites of sodium salicylate. J. Biol. Chem.145, 549–565 (1942).
M. Grootveld and B. Halliwell,2,3-Dihydroxybenzoic acid is a product of human aspirin metabolism. Biochem. Pharmacol.37, 271–280 (1988).
M. S. Alexander, R. M. Husney and A. L. Sagone,Metabolism of benzoic acid by stimulated polymorphonuclear cells. Biochem. Pharmacol.35, 3649–3651 (1986).
A. L.Sagone and R. M. Husney,Oxidation of salicylates by stimulated granulocytes. J. Immunol.138, 2177–2183 (1987).
B. Halliwell and J. M. C. Gutteridge,Detection of hydroxyl radicals in biological systems. InFree Radicals in Biology and Medicine, pp. 35–37. Oxford University Press, Oxford 1986.
D. R. Haynes, M. W. Whitehouse and B. Vernon-Roberts,The prostaglandin E 1 analogue, Misoprostol, regulates inflammatory cytokines and immune functions in vitro like the natural E-prostaglandins (1,2 and 3). Immunology76, 251–257 (1992).
S. Endres, R. Ghorbani, V. E. Kelley, K. Georgilis, G. Lonnemann, J. W. M. van der Meer, J. G. Cannon, T. S. Rogers, M. S. Klempner, P. C. Weber, Schaefer, S. M. Wolff and C. A. Dinarello,The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. New Engl. J. Med.320, 265–271 (1989).
D. R. Haynes, P. F. Wright, M. W. Whitehouse and B. Vernon-Roberts,The cyclooxygenase inhibitor, piroxicam, enhances cytokine-induced lymphocyte proliferation in vitro and in vivo. Immunol. Cell Biol.68, 225–230 (1990).
W. E. Scales, S. W. Chensue, I. Otterness and S. L. Kunkel, Regulation of monokine gene expression: prostaglandin E2 suppresses tumor necrosis factor but not interleukin-1 alpha or beta-mRNA and cell-associated bioactivity. J. Leukoc. Biol.45, 416–421 (1989).
I. G. Otterness, M. L. Bliven, J. D. Eskra, M. Reinke and D. C. Hanson,Regulation of Interleukin-1 production: The role of prostaglandins. Cell Immunol.114, 385–397 (1988).
Y. Zhang, J. Lin and J. Vilack,Synthesis of Interleukin-6 (Interferon-beta 2 /B cell stimulatory factor 2) in human fibroblasts is triggered by an increase in intracellular cyclic AMP. J. Biol. Chem.263, 6177–6182 (1988).
J. L. Webb, InEnzyme and Metabolic Inhibitors, Vol. III, pp. 520–538. Academic Press, New York 1966.
R. K. Rosenthal, T. B. Bayles and K. Fremont-SmithSimultaneous salicylate concentrations in synovial fluid and plasma in rheumatoid arthritis. Arth. Rheum.7, 103–109 (1964).
M. J. H. Smith,Editorial: Prostaglandins and aspirin: an alternative view. Agents and Actions.5, 315–317 (1975).
M. J. H. Smith, A. W. Ford-Hutchinson, J. R. Walker and J. A. Slack,Aspirin, salicylate and prostaglandins. Agents and Actions9, 483–487 (1979).
E. M. Glenn, B. J. Bowman and N. A. Rohloff,Anomalous biological effects of salicylates and prostaglandins. Agents and Actions9, 257–264 (1979).
Author information
Authors and Affiliations
Additional information
The term “oxymetabolites” refers to those diphenols and other products formed primarily by oxygenation, in contrast to other normal metabolites formed by conjugation (with glucuronate, glycine and sulphate), recognising that some oxymetabolites may in turn be conjugated (e.g. gentisate to gentisurate). Production of oxymetabolites is not necessarily mediated by cytochrome-P450 oxygenases: as this report indicates, they may also be formed by interactions, possibly non-enzymatic, with reactive oxygen-derived species generated by inflammatory cells.
Rights and permissions
About this article
Cite this article
Haynes, D.R., Wright, P.F.A., Gadd, S.J. et al. Is aspirin a prodrug for antioxidant and cytokine-modulating oxymetabolites. Agents and Actions 39, 49–58 (1993). https://doi.org/10.1007/BF01975714
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01975714